Clovis Oncology: Up after ovarian cancer drug meets main goal in late-stage study

Clovis Oncology

21/12/2020 14:19

** Shares of drugmaker  CLVS.O  rise 11.6% to $5.47
premarket
    ** CLVS says its drug Rubraca in a late-stage study met the
main goal of improved progression-free survival vs chemotherapy
in relapsed ovarian cancer patients with a tumor mutation who
had received chemotherapy  urn:newsml:reuters.com:*:nBw3bBjSqa
    ** Says median progression-free survival for patients
treated with Rubraca was 7.4 months vs. 5.7 months for those who
received chemotherapy
    ** Ovarian cancer ranks fifth in cancer deaths among women
in the U.S. and European Union, according to co
    ** Stock had fallen 53% YTD as of last close
    

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))